Beam Therapeutics: Great Potential, But Patience Is Needed
Beam Therapeutics Inc. is rated a Buy for its leadership in proprietary base-editing gene therapy, targeting significant unmet needs in hematology and liver diseases. BEAM's risto-cel shows superior efficacy in sickle cell disease, but commercial success hinges on overcoming conditioning protocol challenges and competing with Vertex/Crispr's head start. The liver-targeted BEAM-302 program demonstrates strong early clinical results and could establish a competitive moat, with pivotal data and BLA submission expected in 18–24 months.
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Beats Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to a loss of $1.09 per share a year ago.
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics Inc. (BEAM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Beam Therapeutics: Pivoting From Platform To Execution Stage
Beam Therapeutics Inc. pivots from platform story to execution-driven thesis, with regulatory clarity accelerating BEAM-302 and Risto-cel in 2026. BEAM-302's "in vivo" gene editing for AATD achieved a potential FDA accelerated approval pathway, derisking the lead pipeline and providing a major 2026 catalyst. Risto-cel targets Sickle Cell Disease but faces a crowded ex vivo market; best-in-class data and BLA submission are expected by end of 2026.
BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises
Beam Therapeutics jumps 22% after outlining 2026 pipeline goals, including accelerated approval plans for BEAM-302 and a potential risto-cel BLA filing.
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?
Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal
Beam Therapeutics Inc. remains a Strong Buy, supported by robust BEAM-101 phase 1/2 BEACON trial data in sickle cell disease. BEAM-101 consistently achieved >60% Hemoglobin F induction,
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago.
